Clinical Trial

A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 2, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this observational study is to compare the efficacy and safety of tixocutibine and belizumab in the treatment of systemic lupus erythematosus in patients aged 18-65 years with systemic lupus erythematosus. The main question it aims to answer is: In the overall population of systemic lupus erythematosus: What is the response rate (SRI-4) of the two drugs in treating systemic lupus erythematosus? Which drug has better efficacy and safety? This study is a retrospective study. The participants will not receive any treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-06.
Trial Details
NCT Number NCT07053137
Lead Sponsor Yipeng Liu
Collaborators: Renmin Hospital of Wuhan University, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Beijing Friendship Hospital
Conditions Systemic Lupus Erythematosus, Telitacicept, Belimumab, Efficacy and Safety
Enrollment 180 participants
Start Date 2025-11-30
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-02